| abstract |
The invention relates to compounds blocking or activating the mTOR pathway for use as a medicament in combination with rapamycin or a rapamycin-like compound and/or with metformin or a metformin-like compound and/or with thermal energy, for the treatment of neoplastic diseases, hyperproliferative conditions or other processes wherein mTOR is implicated. Experiments are described which demonstrate that mutational loss of Tsc2 or PTEN or down-regulating Tsc2 or PTEN by shRNA sensitizes cells for rapamycin and metformin and for thermal treatment, with synergies of these three forms of treatments. The invention further relates to a method to predict sensitivity of a tumor to the combination of mTOR pathway inhibition combined with application of thermal energy. |